Cas:32668-14-7 L-Glutamine, methyl ester, hydrochloride manufacturer & supplier

Chemical Name:L-Glutamine, methyl ester, hydrochloride

CAS.NO:32668-14-7

Synonyms:MFCD00237059;L-Glutamine methyl ester hydrochloride;L-glutamine methyl ester monohydrochloride;L-Glutamin-methylester,Hydrochlorid;H-Gln-Ome.HCl;Methyl L-glutaminate hydrochloride (1:1);ZLD0436;L-Glutamine, methyl ester, hydrochloride (1:1);L-Glutamine, methyl ester, hydrochloride

Molecular Formula:C₆H₁₃ClN₂O₃

Molecular Weight:196.632

HS Code:2924199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:369.9ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:95.41000

Exact Mass:196.061462

LogP:0.95480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00237059 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-Glutamine, methyl ester, hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-Glutamine methyl ester hydrochloride Use and application,H-Gln-Ome.HCl technical grade,usp/ep/jp grade.

Related News: “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. L-Glutamine, methyl ester, hydrochloride manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. L-Glutamine, methyl ester, hydrochloride supplier This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. L-Glutamine, methyl ester, hydrochloride vendor “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. L-Glutamine, methyl ester, hydrochloride factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.